Meeting
2014 ASCO Annual Meeting
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.
Authors
Mary L. Disis
University of Washington, Seattle, WA
Mary L. Disis , Andrew L. Coveler , Doreen Higgins , Patricia Fintak , James Ross Waisman , Jessica Reichow , Meredith Slota , Jennifer Childs , Yushe Dang , Lupe G. Salazar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00436254
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 616)
DOI
10.1200/jco.2014.32.15_suppl.616
Abstract #
616
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.
First Author: Mary L. Disis
Poster
2017 ASCO Annual Meeting
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
First Author: Maria Alsina
Poster
2023 ASCO Annual Meeting
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
First Author: Hyo S. Han
Poster
2022 ASCO Annual Meeting
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
First Author: Kim Anna Reiss